Compare Illumina, Inc. (ILMN) vs Procter & Gamble Co (PG) Price & Performance

Illumina, Inc.Trade

Procter & Gamble CoTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs Procter & Gamble Co — how do they compare? Illumina, Inc. trades at $182.09 (market cap $27.94B), while Procter & Gamble Co trades at $148.8 (market cap $347.26B). The key difference: Procter & Gamble Co is far larger — about 12.4× Illumina, Inc.'s market cap, and Procter & Gamble Co pays a 2.92% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.

	ILMN	PG
Market Cap	$27.94B	$347.26B
Sector	Health	Consumer Staples
52-Week High	$194.33	$167.18
52-Week Low	$91.00	$138.10
Enterprise Value	$29.33B	$372.74B
Volume	—	6,423,436
Dividend Yield	—	2.92%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.

Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.

Procter & Gamble Co

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ILMN

Cancer biomarkers market to hit $54.48B by 2032, driven by tech advances and Asia-Pacific growthResearchandmarkets.Com · 4 days agoBullish New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral Illumina's Billion Cell Atlas adds Formation Bio to boost AI-driven drug discovery with massive genomic data.PRNewsWire · 4 days agoBullish View details →

DIVO ETF up 6.6% YTD but faces pressure from high Treasury yields and low volatility.24/7 Wall Street · 3 days agoNeutral Vanguard High Dividend Yield ETF offers durable income with strong dividend coverage and steady returns.24/7 Wall Street · 3 days agoBullish SPYI ETF yields 12% but faces pressure as volatility drops and Treasury yields rise.24/7 Wall Street · 3 days agoNeutral View details →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

About Procter & Gamble Co

The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.